Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide or derivative thereof and application of polypeptide or derivative in influenza virus infection

A technology of influenza virus infection and peptide derivatives, applied in the field of novel polypeptide or protein drugs

Active Publication Date: 2014-11-19
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no related reports on the design and development of inhibitors that block the entry of influenza virus based on HA1 and target binding to host cell receptors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide or derivative thereof and application of polypeptide or derivative in influenza virus infection
  • Polypeptide or derivative thereof and application of polypeptide or derivative in influenza virus infection
  • Polypeptide or derivative thereof and application of polypeptide or derivative in influenza virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1: Chemical Synthesis of Influenza Virus Hemagglutinin Peptide

[0039] According to the amino acid sequence of SEQ ID NO: 1-8 in the sequence listing, a peptide molecule (18 amino acids in length) with a purity greater than 90% was synthesized by using the solid-phase peptide synthesis method (SYMPHONY type 12-channel peptide synthesizer), and passed through HPLC liquid Purity and molecular weight were identified by phase chromatography and MS mass spectrometry. The HPLC purity identification chart and mass spectrogram of SEQ ID NO: 1-8 are shown in Figure 2.

Embodiment 2

[0040] Example 2: Preparation of highly pathogenic H5N1 influenza recombinant virus and determination of the inhibitory activity of influenza virus hemagglutinin peptide on highly pathogenic H5N1 influenza recombinant virus infection

[0041] 1) Preparation of highly pathogenic H5N1 influenza recombinant virus

[0042] The preparation method of the highly pathogenic H5N1 influenza virus is as follows: the HIV vector plasmid (pNL4-3.Luc.R.E., obtained from NIH) and the plasmid of HA cloned into the mammalian cell expression vector pcDNA3.1 are co-transfected into 293T cells ( Human embryonic kidney cells) to produce recombinant virus particles with HIV as the core and wrapped with HA coat protein. The virus particle has the following characteristics: 1) Since the coat protein is hemagglutinin, the selectivity of the virus particle to the host cell depends on the characteristics of the hemagglutinin. The HA protein in the experiment is derived from the highly pathogenic H5N1 in...

Embodiment 3

[0047] Example 3: Preparation of Seasonal H1N1 Human Influenza Virus and Determination of Influenza Virus Hemagglutinin Peptides Inhibiting Pathogenicity of Host Cells Infected by Seasonal H1N1 Human Influenza Virus

[0048] 1) Preparation of seasonal H1N1 human influenza virus:

[0049] In order to detect the effect of influenza virus hemagglutinin peptides on different species and strains of influenza virus infection, we prepared seasonal H1N1 human influenza virus A / Puerto Rico / 8 / 1934 (H1N1) strains that infect humans, and the preparation method The method is as follows: inoculate the allantoic cavity and amniotic cavity of 9-day-old chicken embryos with the virus stock solution, culture the chicken embryos at 37°C for 2-3 days, harvest the virus in the allantoic fluid and amniotic fluid, centrifuge, aliquot, and store at -70°C. Select MDCK cells (canine kidney cells), a sensitive cell line suitable for the growth of influenza virus, as virus-infected cells, DMEM+0.2%BSA+2μ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to polypeptide, protein or peptide-like medicine from influenza virus hemagglutinin, and a method of the polypeptide, belongs to the technical field of biological medicines, and in particular relates to eight influenza virus hemagglutinin fragment peptides which can block influenza virus infection and have the serial numbers SEQ ID NO.1 to SEQ ID NO.8. The fragment peptides can inhibit and block infection of different species and influenza viruses of different subtypes to a host, including multiple influenza virus strains such as highly pathogenic avian influenza virus, seasonal human influenza virus and the like. The invention provides the peptide sequence (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), derivative peptides (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), peptide compositions and independent or united applications of peptides in preventing or treating influenza virus, such as medicine combination of peptides provided by the invention and other anti-influenza medicines.

Description

technical field [0001] The present invention relates to the anti-influenza virus infection method in the technical field of biomedicine and the polypeptide or protein drug used therein, including peptide sequence, peptide derivative, peptide composition, and its use in the preparation of anti-influenza virus drug. The present invention relates to a novel polypeptide or protein drug derived from the HA1 subunit of the surface protein hemagglutinin of influenza virus, which can prevent and treat the infection of various influenza virus strains, including existing viruses of different subtypes (such as human influenza and avian influenza) , including the highly pathogenic H5N1 influenza virus that can infect humans) and the infection inhibition of future viruses that mutate existing viruses (such as future mutants of avian influenza that may be transmitted from person to person), and the combination with existing Or future combined use of anti-influenza drugs. Background techni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/11C12N15/44C12N15/85C12N5/10A61K48/00A61K39/145A61P31/16
CPCA61K39/00C07K14/005C12N2760/16122C12N2760/16134
Inventor 郭颖陈勍郭彦伸
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com